LUGPA Policy Brief: HHS Launches Department-Wide Clinical Trials Reform Initiative

July 2026

At-a-Glance

What Happened

The U.S. Department of Health and Human Services (HHS) launched a department-wide initiative to modernize the nation's clinical research enterprise, accelerate drug development, and expand clinical trial activity in the United States. The effort coordinates actions across the FDA, NIH, ARPA-H, ONC, and OIG to streamline research, reduce regulatory barriers, improve patient recruitment, and encourage greater investment in domestic clinical trials.

Why It Matters

Clinical trials are essential to developing new therapies for prostate cancer, bladder cancer, kidney cancer, and other urologic conditions. Modernizing the clinical research system could expand opportunities for community-based physician practices to participate in research and improve patient access to innovative treatments.

LUGPA Position

LUGPA supports efforts to modernize clinical research while maintaining rigorous standards for patient safety and scientific integrity. Independent physician-led practices should have meaningful opportunities to participate in federally supported clinical research initiatives.

Key Initiative Highlights

FDA

• Developing a pilot program to shorten timelines from drug discovery to first-in-human clinical trials.
• Issuing guidance intended to streamline drug development and, in appropriate cases, support approval based on a single high-quality pivotal trial with confirmatory evidence.

NIH and Federal Research Agencies

• Expanding the use of artificial intelligence, real-world evidence, and pragmatic clinical trial designs.
• Continuing investments in precision medicine, rare disease research, and cancer clinical trial modernization.
• Exploring integration of clinical trial opportunities into electronic health records.
• Supporting AI and machine learning tools to improve trial design and efficiency.

Implications for Independent Urology Practices

Potential Benefits

• Expanded opportunities for community-based practices to participate in clinical research.
• Faster patient access to emerging therapies.
• Increased collaboration with industry sponsors and research organizations.
• Greater use of EHR tools to identify eligible patients for clinical trials.

Potential Challenges

• Additional infrastructure and compliance requirements for participating practices.
• Risk that academic medical centers continue to receive the majority of research opportunities unless community practices are intentionally included.
• Several aspects of the initiative remain under development, and implementation details could affect physician participation.

LUGPA Recommendations

LUGPA encourages HHS to:

• Ensure independent physician practices are fully included in clinical research initiatives.
• Reduce unnecessary administrative barriers while maintaining patient protections.
• Promote clinical trial participation in community-based settings.
• Support practical, interoperable EHR integration for clinical trial recruitment.
• Monitor implementation to ensure equitable access for patients and physician practices.

Bottom Line

HHS's initiative represents a significant federal effort to modernize clinical research and strengthen U.S. biomedical innovation. If implemented effectively, these reforms could expand research opportunities for independent urology practices, improve patient access to innovative therapies, and strengthen the role of community-based physicians in clinical research. LUGPA will continue to monitor implementation and advocate for policies that ensure independent specialty practices are full participants in the evolving clinical research ecosystem.